AN ACT to create and enact a new section to chapter 26.1-36 of the North Dakota Century Code, relating to individual and group health insurance coverage of insulin drugs and supplies; and to amend and reenact section 54-52.1-04.18 of the North Dakota Century Code, relating to health insurance benefits coverage of insulin drugs and supplies.
House Bill No. 1114 aims to establish out-of-pocket limitations for health insurance coverage related to insulin drugs and medical supplies necessary for diabetes management in North Dakota. The bill mandates that health benefit plans must provide coverage for insulin and related medical supplies, ensuring that individuals do not pay more than $25 for a 30-day supply of covered insulin or medical supplies. The legislation also prohibits any additional cost-sharing requirements that would increase out-of-pocket expenses beyond this limit.
Additionally, the bill clarifies definitions for insulin drugs and medical supplies, explicitly excluding devices such as insulin pumps and continuous glucose monitors from the coverage requirements. It also outlines that if the application of these out-of-pocket limits would affect the eligibility of a health benefit plan for health savings accounts, the limits would not apply until the minimum deductible is met. This provision aims to balance the needs of individuals with diabetes while ensuring compliance with federal regulations.
The bill amends existing statutes to align with the new coverage requirements and emphasizes the importance of making insulin and necessary supplies more affordable for those managing diabetes. It reflects a growing concern over the rising costs of insulin and the financial burden it places on individuals and families.
Overall, HB1114 is positioned as a significant step towards improving access to essential diabetes management resources, potentially benefiting many North Dakotans living with diabetes.
The enactment of HB1114 will have a direct impact on health insurance policies in North Dakota by requiring all health benefit plans to include specific coverage for insulin drugs and related medical supplies. This will likely lead to a reduction in out-of-pocket expenses for individuals managing diabetes, making essential medications and supplies more accessible. The bill also modifies existing laws to ensure that the out-of-pocket maximums are adhered to, which may influence how insurance companies structure their plans and pricing strategies moving forward.
The sentiment surrounding HB1114 appears to be largely positive, with support for the bill reflecting a collective recognition of the need for affordable insulin and diabetes management supplies. The committee discussions and voting history indicate a favorable reception among legislators, as evidenced by the significant majority votes in both the House and Senate. However, there may be some concerns regarding the implications for insurance providers and the potential financial impact on the healthcare system.
Notable points of contention may arise from insurance companies and pharmacy benefits managers regarding the financial implications of the mandated out-of-pocket limits. Some stakeholders may argue that such regulations could lead to increased premiums or limit the availability of certain plans. Additionally, the exclusion of certain diabetes management devices from coverage requirements might prompt discussions about the adequacy of support for individuals who rely on these technologies.